NEW YORK (TheStreet) -- Mylan
(MYL - Get Report) shares are down -2.1% to $46.93 on Thursday after the company lowered the top line of its full year earnings guidance to $3.45 from $3.60, while also lowering its top line full year revenue guidance to $8 billion from $8.2 billion.
The pharmaceutical company reported second quarter earnings of 69 cents per diluted share, 3 cents short of analysts expectations, on revenue of $1.84 billion that fell short of the $1.9 billion analysts were expecting.
Must Read: Warren Buffett's 25 Favorite Stocks
TheStreet Ratings team rates MYLAN INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:"We rate MYLAN INC (MYL) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated." Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: MYL Ratings Report
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts